CSI Market
Sign In | Register

Lumos Pharma Inc (LUMO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LUMO Annual Cash Flow →
Examining cash flow movements between Lumos Pharma Inc and Sep 30 2023 reveals how Sep 30 2024 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-25.46
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation1.35
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Debt Instrument Decrease Forgiveness-
Forgiveness Of Notes Receivable From Related Parties-
Increase Decrease In State Research And Development Credit Receivable-
Preferred Stock Accretion Of Redemption Discount-
Capital Expenditures Incurred But Not Yet Paid-
Stock Issued-
Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.04
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.37
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.17
Other Working Capital0.00
Other Noncash Income0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-24.28
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Maturities Of Marketable Securities1.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses and Interests in Affiliates0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-35.10
Repayments Advances Of Notes Receivable For Common Stock-
Proceeds From Subsidiary Common Stock Option Exercise-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents35.08
Proceeds From Sale Of Under Controlled Equity Offering Net Of Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.72
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-24.28
Total Cash Flow-21.56
4 historic quarters locked

Sign in to unlock the full Lumos Pharma Inc cash flow history.

Sign In Create Free Account

About Lumos Pharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001126234-24-000097

Figures are derived from filed reports and may be restated. Historical data is subject to revision.